Page last updated: 2024-12-09

1,3-dimethyl-8-(4-phenyl-1-piperazinyl)-7H-purine-2,6-dione

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

1,3-dimethyl-8-(4-phenyl-1-piperazinyl)-7H-purine-2,6-dione, also known as **pentoxifylline**, is a medication that has been used for several decades to treat a variety of medical conditions.

Here's a breakdown of its structure, function, and importance in research:

**Structure:**

* **Pentoxifylline** is a synthetic compound belonging to the methylxanthine class.
* It has a purine ring structure, similar to caffeine and theophylline.
* The 1,3-dimethyl part refers to two methyl groups attached to the purine ring at positions 1 and 3.
* The 8-(4-phenyl-1-piperazinyl) part indicates a piperazine ring with a phenyl group attached at position 4, and this entire group is linked to the purine ring at position 8.
* The 7H-purine-2,6-dione part specifies the presence of two ketone groups at positions 2 and 6 of the purine ring.

**Function:**

Pentoxifylline has multiple pharmacological actions:

* **Vasodilation:** It relaxes blood vessels, improving blood flow. This effect is primarily mediated by its inhibition of phosphodiesterase, an enzyme that breaks down cyclic adenosine monophosphate (cAMP), a signaling molecule that promotes vasodilation.
* **Anti-inflammatory:** Pentoxifylline reduces inflammation by inhibiting the production of inflammatory mediators like tumor necrosis factor-alpha (TNF-α).
* **Anti-platelet:** It reduces platelet aggregation, making the blood less prone to clotting.
* **Antioxidant:** Pentoxifylline can protect cells from damage caused by free radicals.

**Importance in Research:**

Pentoxifylline is of ongoing research interest for several reasons:

* **Treatment of Peripheral Artery Disease (PAD):** It is commonly used to improve blood flow and reduce symptoms in patients with PAD. Studies continue to explore its effectiveness in treating PAD and its potential role in preventing complications.
* **Neuroprotection:** Pentoxifylline has been shown to protect neurons from damage in various models of stroke and neurodegenerative diseases. Research focuses on its potential therapeutic benefits for these conditions.
* **Cancer Treatment:** Pentoxifylline has demonstrated anti-cancer effects in several studies, and its mechanisms of action are being investigated.
* **Anti-Inflammatory Applications:** Its anti-inflammatory properties make it a potential treatment for conditions such as inflammatory bowel disease, arthritis, and autoimmune disorders.

**Current Research:**

* **Dosage and Administration:** Research is ongoing to optimize the dosage and delivery methods of pentoxifylline for various conditions.
* **Combination Therapies:** Studies are exploring the effectiveness of pentoxifylline in combination with other drugs for treating complex diseases.
* **Mechanism of Action:** Scientists are investigating the specific molecular mechanisms underlying pentoxifylline's various pharmacological effects to further understand its therapeutic potential.

In summary, 1,3-dimethyl-8-(4-phenyl-1-piperazinyl)-7H-purine-2,6-dione (pentoxifylline) is a multifaceted drug with significant research implications. Its potential to treat a wide range of diseases continues to be investigated, making it a valuable subject of ongoing scientific inquiry.

Cross-References

ID SourceID
PubMed CID949903
CHEMBL ID1731509
CHEBI ID108226

Synonyms (17)

Synonym
smr000294930
1,3-dimethyl-8-(4-phenyl-1-piperazinyl)-3,7-dihydro-1h-purine-2,6-dione
MLS000664957
STK164790
1,3-dimethyl-8-(4-phenylpiperazin-1-yl)-3,7-dihydro-1h-purine-2,6-dione
OPREA1_746113
CHEBI:108226
1,3-dimethyl-8-(4-phenylpiperazin-1-yl)-7h-purine-2,6-dione
AKOS002317647
HMS2702C08
CCG-22350
AB00358981-08
CHEMBL1731509
1,3-dimethyl-8-(4-phenyl-1-piperazinyl)-7h-purine-2,6-dione
Q27186920
NCGC00292511-01
1,3-dimethyl-8-(4-phenylpiperazino)-3,7-dihydro-1h-purine-2,6-dione
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
piperazines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (7)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency44.66840.003245.467312,589.2998AID2517
ATAD5 protein, partialHomo sapiens (human)Potency14.57500.004110.890331.5287AID504466
TDP1 proteinHomo sapiens (human)Potency23.10930.000811.382244.6684AID686978
67.9K proteinVaccinia virusPotency5.62340.00018.4406100.0000AID720579
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency79.43280.035520.977089.1251AID504332
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency18.35640.00419.984825.9290AID504444
Rap guanine nucleotide exchange factor 4Homo sapiens (human)Potency28.18383.981146.7448112.2020AID720711
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (10)

Processvia Protein(s)Taxonomy
adaptive immune responseRap guanine nucleotide exchange factor 4Homo sapiens (human)
G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 4Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 4Homo sapiens (human)
calcium-ion regulated exocytosisRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of exocytosisRap guanine nucleotide exchange factor 4Homo sapiens (human)
insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
positive regulation of insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of synaptic vesicle cycleRap guanine nucleotide exchange factor 4Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein-macromolecule adaptor activityRap guanine nucleotide exchange factor 4Homo sapiens (human)
small GTPase bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
cytosolRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]